October 26, 2011 –Lantheus Medical Imaging announced it has been awarded three-year supplier contracts with Premier Purchasing Partners, the group purchasing unit of the Premier healthcare alliance, in the category of cardiac ultrasound contrast media for its ultrasound contrast agent, Definity Vial for (perflutren lipid microsphere) Injectable Suspension, and its magnetic resonance angiography (MRA) blood pool imaging agent, Ablavar (gadofosveset trisodium).

October 26, 2011 – Older men whose bodies produce higher levels of testosterone may be protected against heart attacks and strokes, new medical research suggests.

October 26, 2011 – St. Jude Medical announced it has received U.S. Food and Drug Administration (FDA) clearance for its Ilumien system, the first integrated diagnostic technology that combines optical coherence tomography (OCT) and fractional flow reserve (FFR) technologies on one platform. The combined system offers physicians advanced physiological and anatomical insight to improve the diagnosis and treatment of coronary artery disease.

October 25, 2011 — Stentys S.A. announced the publication of the results of the APPOSITION I clinical study in the September issue of the medical journal EuroIntervention.

October 24, 2011 — NeoStem Inc. and Amorcyte Inc announced the closing of their previously publicized merger transaction following approval by the shareholders of both companies on Oct. 14, 2011. NeoStem closed on a financing raising $16.5 million in gross proceeds on July 22. The company intends to initiate, no later than the first quarter of 2012, a Phase 2 clinical trial for Amorcyte's lead product candidate, AMR-001, for the treatment of acute myocardial infarction (AMI).

October 24, 2011 — New study results reveal several underlying causes of non-ischemic sudden cardiac death (SCD) — those not related to coronary artery disease (CAD) — including alcohol, obesity and myocardial fibrosis. The study, published in the October edition of HeartRhythm, the official journal of the Heart Rhythm Society (HRS), also reinforces CAD as one of the most prevalent causes of SCD in the general population.

October 24, 2011 — BioCrossroads’ Indiana Seed Fund has announced its twelfth investment, committing $300,000 to medical device start-up Zorion Medical. Zorion is developing a breakthrough device combining novel biomaterials with known drug and drug delivery technology in a unique design to treat cardiovascular disease.

October 24, 2011, — A new study demonstrates that angiotensin-converting enzyme (ACE) inhibitors taken in the first trimester of pregnancy pose no greater risk of birth defects than any other type of high blood pressure medication. The study, conducted by the U.S. Department of Health and Human Services’ (HHS) Agency for Healthcare Research and Quality (AHRQ), suggests high blood pressure itself may increase the risk of birth defects.

October 24, 2011 – As a result of the long-standing relationship between Philips Healthcare and ScImage Inc., the two companies are pleased to announce a newly developed integration option between ScImage’s PicomEnterprise picture archive and communications systems (PACS) and the Philips PageWriter TC series cardiographs. As a team, the two companies believe this interface will greatly simplify clinical electrocardiogram (ECG) workflow and reduce the complexity normally associated with custom integration.

 

October 24, 2011 – The American College of Cardiology (ACC) announced it is expanding its outpatient PINNACLE Registry with a new platform focusing on atrial fibrillation (AF), including the next generation of anticoagulants.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now